Cost Comparison: PCSK9 Inhibitors vs Inclisiran
PCSK9 monoclonal antibodies (evolocumab and alirocumab) are substantially less expensive than inclisiran, with annual costs approaching approximately $4,500 per year for PCSK9 mAbs compared to significantly higher costs for inclisiran, making PCSK9 mAbs the more cost-effective choice for patients already on high-intensity statin plus ezetimibe with LDL-C around 50 mg/dL.
Annual Cost Analysis
PCSK9 Monoclonal Antibodies (Evolocumab/Alirocumab)
The 2022 ACC Expert Consensus explicitly states that the annual cost of PCSK9 mAbs (evolocumab and alirocumab) is approaching approximately $4,500 per year 1. This represents a substantial decrease from their initial FDA approval pricing in 2015, with prices dropping significantly to approach cost-effectiveness thresholds 1.
Inclisiran
While the guidelines do not provide specific pricing for inclisiran, recent cost-effectiveness analyses reveal:
- First-year costs for inclisiran are substantially higher, with one analysis showing costs of 31,329€ (approximately $34,000 USD) in the first year 2
- Subsequent years remain expensive: 26,108€ (approximately $28,000 USD) averaged over the first two years and 22,975€ (approximately $25,000 USD) averaged over five years 2
- Another analysis estimated inclisiran would need to be priced 60% lower than current PCSK9 inhibitors to be cost-effective 3
Cost Per Effectively Treated Patient
When examining cost-effectiveness for achieving LDL-C targets (<55 mg/dL with ≥50% reduction):
- Evolocumab 140 mg Q2W: €6,200 per effectively treated patient annually 2
- Alirocumab 150 mg Q2W: €7,127 per effectively treated patient annually 2
- Inclisiran: €19,255-31,329 per effectively treated patient (depending on year) 2
This translates to inclisiran being approximately 3-5 times more expensive per effectively treated patient compared to PCSK9 mAbs.
Clinical Context for Your Patient
For a patient already on high-intensity statin plus ezetimibe with LDL-C approximately 50 mg/dL:
This patient may not require additional therapy at all, as they are already near the very high-risk target of <55 mg/dL 1. However, if additional LDL-C lowering is deemed necessary:
- PCSK9 mAbs are preferred based on both cost and evidence 1
- The 2022 ACC guidelines note that no outcome studies exist for inclisiran 1, whereas PCSK9 mAbs have proven cardiovascular outcomes data from FOURIER and ODYSSEY Outcomes trials 1, 4
- PCSK9 mAbs provide marginally superior LDL-C reduction (≈60%) compared to inclisiran (≈50%) 5
Dosing and Administration Cost Considerations
PCSK9 mAbs:
- Evolocumab: 140 mg every 2 weeks or 420 mg monthly
- Alirocumab: 75-150 mg every 2 weeks or 300 mg monthly
- Require refrigeration and subcutaneous injection 1
Inclisiran:
- Initial dose, repeat at 3 months, then every 6 months
- Also requires refrigeration and subcutaneous injection
- Despite less frequent dosing, annual costs remain substantially higher 2, 3
Important Caveats
The decreased costs and improved access to PCSK9 mAbs have made them increasingly feasible as lipid-lowering agents 1. The 2019 AHA/ACC guidelines noted PCSK9 inhibitors had "low cost value" at mid-2018 list prices (>$150,000 per QALY) 6, but the 2022 ACC consensus confirms prices have dropped substantially since then 1.
Inclisiran lacks long-term cardiovascular outcomes data, which is a critical consideration when choosing between these agents 1. The proven mortality and morbidity benefits of PCSK9 mAbs from large randomized trials provide additional value beyond simple cost comparison 1, 4.